Overview

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry Eye Disease (DED).
Phase:
Phase 2
Details
Lead Sponsor:
Novaliq GmbH
Treatments:
Cyclosporine
Cyclosporins
Ophthalmic Solutions
Pharmaceutical Solutions